Program in Medical Technology

ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule

LEUVEN, Belgium, June 25 /PRNewswire-FirstCall/ -- - Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and d...

Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneou...

National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion

Goal is to Enhance Patient Safety and Reduce Health Care Costs BETHESDA, Md., May 7 /PRNewswire-USNewswire/ -- Beginning today, nine hospitals will join in a pilot program, contributing data on adverse events associated with blood transfusions. By analyzing the data collected, it w...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

Two Phase 3 studies to start in the second half of this year BERLIN and TARRYTOWN, N.Y., April 30 /PRNewswire-FirstCall/ -- Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced that the companies are extending their global development program for VEGF Trap...

Drug Development Program Started Based on CAP(R) Human Cell Line

COLOGNE, Germany, March 3 /PRNewswire/ -- - New Platform May Provide Solutions for Many RA-Patients Around the World Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the sta...

SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists

CHICAGO, March 2 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) and the American College of Obstetricians and Gynecologists (ACOG) have jointly developed a breast disease fellowship training program for gynecologic oncologists. Supported by a grant of $75,000 fr...

Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- At the 5th World Health Organization Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Novavax...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to...

InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3

BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market open on Tuesday, February 3. InterMune will conduct a confer...

AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi

MINNEAPOLIS, Jan. 29 /PRNewswire/ -- AGA Medical Corporation today launched a web-based stroke education and awareness program featuring Tedy Bruschi, a professional football player who suffered a stroke in February 2005, subsequently recovered and returned to his career. The unique online educati...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

OSLO, Norway, January 14 /PRNewswire-FirstCall/ -- - Results Highlight the Potential of Alpharadin to Treat Bone Metastases in Major Cancer Indications Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that with the results of the BC1-04 study reported today i...

ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell

LEIDEN, The Netherlands, January 13 /PRNewswire/ -- ProFibrix B.V., today announced that it has concluded a commercial license agreement with Crucell N.V. (Euronext, NASDAQ: CRXL ; Swiss Exchange: CRX) for PER.C6(R), a unique human protein production platform. The PER.C6(R) platform allows P...

ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease

LEUVEN, Belgium, January 9 /PRNewswire-FirstCall/ -- - ThromboGenics' Lead Product to be Studied in the Treatment of Vitreomacular Adhesion in the US and Europe ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, va...

Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009

NEW YORK, LONDON and HAMILTON, Bermuda, Dec. 16 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") announced today that the databases have been locked and preliminary analyses completed on the two double-blinded studies of XERECEPT (R) (corticorelin acetate), as a treatment fo...

Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer

PRINCETON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer. Studies suggest t...

Healthy Bones Program Reduces Hip Fractures by 37 Percent, Kaiser Permanente Study Finds

Largest Study of Its Kind PASADENA, Calif., Nov. 4 /PRNewswire/ -- Proactive measures can reduce hip fracture rates by an average of 37.2 percent -- and as much as 50 percent -- among those at risk, according to a study conducted by Kaiser Permanente Southern California....

MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine

GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most ...

Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants

DETROIT, Oct. 14 /PRNewswire-USNewswire/ -- Susan G. Komen for the Cure(R) recently announced the distribution of an unprecedented $100 million in grants to American and international scientists this year alone to fast track breast cancer research. Grants were also made by local Komen Affilia...

Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center

Advances in diagnostics and genetic testing give women answers about their risks DAYTON, Ohio, Oct. 1 /PRNewswire/ -- According to the U.S. Cancer Statistics Working Group (2007), an estimated 182,460 new cases of breast cancer will be diagnosed in American women...

Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures

PHILADELPHIA, Sept. 30 /PRNewswire-USNewswire/ -- The following is being released by The Philadelphia AIDS Consortium: WHO: Parent Organization: The Philadelphia AIDS Consortium in partnership with its network of eleven (11) community-based organization sites located throughout the tri-state...

Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate

PURCHASE, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (Nasdaq: NXXI ), the developer and marketer of nutritional supplements under the Iceland Health Chromax(R), and Diabetes Essentials(TM) brands that help consumers manage blood sugar levels, improve cardiovascular health, en...

Rabies Vaccination Program Underway in Western Pennsylvania

HARRISBURG, Pa., Sept. 2 /PRNewswire-USNewswire/ -- An annual program that helps control rabies in wild animals is underway in western Pennsylvania, Agriculture Secretary Dennis Wolff said today. The oral rabies vaccination baiting program covers all or parts of Allegheny, Armstrong, Beaver,...

Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth

GOTEBORG, Sweden, September 1 /PRNewswire/ -- Calabar AB, a privately held pharmaceutical company developing therapies for treating dry mouth, today announced a EUR 350,000 equity financing from the investment company Karolinska Development AB. The financing will take Calabar's product through...

Telik's Proteasome Inhibitor Program Meets a Preclinical Development Milestone

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced today that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is a...

Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus

Medarex to Receive Milestone Payment from MedImmune PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemi...

Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti...

Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic

~ Initiates IDX184 Phase I Clinical Study and Advances HCV Protease Inhibitor and Non-Nucleoside Polymerase Inhibitor Clinical Candidates into IND-Enabling Preclinical Studies ~ CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX...

Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008

SAN DIEGO, July 28 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its ...

Small Business Innovation Research Program Awards Grant to Biomoda

Company developing proposals to fund clinical studies for early detection of lung cancer ALBUQUERQUE, N.M., June 25 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) ( http://www.biomoda.com ), a development stage medical diagnostics company, announc...

Pharmaxis Establishes Named Patient Program for Bronchitol

SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of IDIS Limited to manage and provide eligible patients worldwide with access to Bronchitol through a Named Patient Program. The program will allow patients who are ...

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies

Olympus Corporation to Support the Joint Program through the Provision of Novel Imaging Systems Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies into Clinical Trials in Ovarian Cancer PHILADELPHIA, TOKYO and WOBURN, Mass, J...

Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain

Cato Research Signed as Strategic Partner for the Phase 3 Program LA JOLLA, Calif., June 16 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company developing non-invasive, topically administered medications, today announced th...

Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions

CAMBRIDGE, Mass., June 9 /PRNewswire/ -- Radius Health ("Radius") announced today that the company has selected the first lead candidate, RAD140, from its internal nonsteroidal selective androgen receptor modulator ("SARM") discovery program, for full preclinical development as a potential the...

Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows

ROCHESTER, Minn., June 4 /PRNewswire-USNewswire/ -- People recovering from acute heart problems such as heart attack and heart surgery are more likely to develop habits to control heart attack risk factors when they meet regularly with cardiac "disease managers," according to researchers at Ma...

Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity

Improvement Noted in Management of Transplant Recipients with Cancer HERSHEY, Pa., June 1 /PRNewswire/ -- The management of immunosuppression in post-transplant patients with cancer is challenging. Clinicians must balance the need to treat the malignancy effectively while simultaneously moni...

Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma

Related Clinical Study Shows Potential Utility of Short-Course High-Dose Therapy BERKELEY HEIGHTS, N.J., May 30 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced preliminary results that have shown a high objective response rate in...

Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting

Efficacy and safety data support potential of asenapine in the treatment of schizophrenia and bipolar I disorder WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that an overview of asenapine clinical trials from the Olympia p...

Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update

Phase III Clinical Trial of Acetavance(TM) for the Treatment of Fever Achieves Primary Endpoint Phase III Clinical Trial of Omigard(TM) Completes Patient Enrollment SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ), a biopharmaceu...

Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, ...

Colorado Cancer Research Program Will Host Golf Event to 'Drive' the Message that Clinical Trials Play a Vital Role in the Quest to Find a Cure for Cancer

DENVER, April 28 /PRNewswire-USNewswire/ -- The Colorado Cancer Research Program (CCRP) invites golfers to participate in its second annual "Drive for a Cure" Golf Tournament on May 19 at the Valley Country Club, 14601 Country Club Drive, Aurora. The private club is one of Denver's premier gol...